var data={"title":"Albumin solution: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Albumin solution: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5576?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=albumin-solution-drug-information\" class=\"drug drug_general\">see &quot;Albumin solution: Drug information&quot;</a> and <a href=\"topic.htm?path=albumin-solution-patient-drug-information\" class=\"drug drug_patient\">see &quot;Albumin solution: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130903\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Albuked 25;</li>\n      <li>Albuked 5;</li>\n      <li>Albumin-ZLB;</li>\n      <li>Albuminar-25;</li>\n      <li>Albuminar-5;</li>\n      <li>AlbuRx;</li>\n      <li>Albutein;</li>\n      <li>Buminate;</li>\n      <li>Flexbumin;</li>\n      <li>Human Albumin Grifols;</li>\n      <li>Kedbumin;</li>\n      <li>Plasbumin-25;</li>\n      <li>Plasbumin-5</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130904\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Alburex-25;</li>\n      <li>Alburex-5;</li>\n      <li>Albutein 25%;</li>\n      <li>Albutein 5%;</li>\n      <li>Octalbin 25%;</li>\n      <li>Octalbin 5%;</li>\n      <li>Plasbumin-25;</li>\n      <li>Plasbumin-5</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050830\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Blood Product Derivative</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Plasma Volume Expander</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11431407\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Albumin <b>5%</b> should be used in hypovolemic or intravascularly depleted patients; albumin <b>25%</b> should be used in patients with fluid or sodium restrictions (eg, patients with hypoproteinemia and generalized edema, or nephrotic syndrome); use the 25% concentration with extreme caution in neonates, due to risk of intraventricular hemorrhage (from rapid expansion of the intravascular volume); infuse slowly. Dose depends on condition of patient:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ascites with hypoalbuminemia:</b> 25% albumin: IV: 1 g/kg/dose over 2 to 3 hours; may repeat up to 3 times per day until albumin is &gt; 2.5 g/dL (Giefer 2011; Sabri 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemolytic disease of the newborn:</b>  25% albumin: IV: 1 g/kg/dose administer prior to or during plasma exchange</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypovolemia, plasma volume expansion:</b> 5% albumin: IV: 0.5 to 1 g/kg/dose (10 to 20 <b>mL</b>/kg/dose) over 60 minutes (may be administered more rapidly over at least 15 to 20 minutes for use in shock) (Cloherty 2012; Kliegman 2007). <b>Note:</b> Normal saline (or blood) are preferred for volume expansion in the delivery room (AHA [Kattwinkel 2010]; AHA [Wyckoff 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypotension:</b> Limited data available: 5% albumin:  IV: 0.5 g/kg/dose (10 <b>mL</b>/kg/dose) over 15 to 20 minutes; may repeat once if necessary. Dosing from a study comparing albumin to NS for hypotension in newborns (&lt;24 hours old); neonates in the albumin treatment group (n=49, GA 30.8 &plusmn; 4.4 weeks) had a greater improvement in blood pressure and were less likely to require subsequent vasopressors compared to the NS treatment arm (n=52, GA 30.1 &plusmn; 4.1 weeks) (Lynch 2008)  Another study using the same dose, found no statistically significant difference between neonates receiving albumin (n=21, GA: 25 to 40 weeks) compared to NS (n=20, GA: 25 to 40 weeks) (Oca 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050824\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=albumin-solution-drug-information\" class=\"drug drug_general\">see &quot;Albumin solution: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Albumin <b>5%</b> should be used in hypovolemic or intravascularly depleted patients; albumin <b>25%</b> should be used in patients with fluid or sodium restrictions (eg, patients with hypoproteinemia and generalized edema, or nephrotic syndrome). Dose depends on condition of patient:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ascites with hypoalbuminemia:</b> Limited data available: Infants, Children, and Adolescents: 25% albumin: IV: 1 g/kg/dose over 2 to 3 hours; may repeat up to 3 times per day until albumin is &gt; 2.5 g/dL; maximum dose: 25 g/dose (Giefer 2011, Sabri 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypovolemia, plasma volume expansion, including hypovolemic shock</b> (SCCM [Dellinger 2013]): Infants, Children, and Adolescents: 5% albumin: IV: 0.5 to 1 g/kg/dose (10 to 20 <b>mL</b>/kg/dose) over 5 to 10 minutes. Usual adult dose: 12.5 to 25 g/dose (250 to 500 <b>mL</b>/dose). May repeat after 30 minutes if response is not adequate (Kleigman 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Large volume paracentesis:</b> Limited data available: Infants, Children, and Adolescents: 5% or 25% albumin: IV: 0.5 to 1 g/kg over 1 to 2 hours after paracentesis (Giefer 2011, Kramer 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nephrotic syndrome edema, refractory:</b> Infants, Children, and Adolescents: 25% albumin:  IV: 0.5 to 1 g/kg/dose over 30 to 60 minutes followed by diuretic therapy (Gipson 2009; Kliegman 2011; Robinson 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Usual dose:</b> IV: 25 g; initial dose may be repeated in 15 to 30 minutes if response is inadequate</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypovolemia:</b> 5% albumin: IV: 12.5 to 25 g (250 to 500 mL); repeat as needed. <b>Note:</b> May be considered after inadequate response to crystalloid therapy and when nonprotein colloids are contraindicated. The volume administered and the speed of infusion should be adapted to individual response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosing adjustments provided in the manufacturer's labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosing adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130890\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Albumin-ZLB: 5% (250 mL, 500 mL); 25% (50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Albuminar-5: 5% (250 mL, 500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Albuminar-25: 25% (50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Albutein: 25% (50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Buminate: 5% (250 mL, 500 mL); 25% (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plasbumin-5: 5% (50 mL, 250 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plasbumin-25: 25% (20 mL, 50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5% (50 mL [DSC]); 25% (50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Albuked 5: 5% (250 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Albuked 25: 25% (50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AlbuRx: 5% (250 mL, 500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Albutein: 5% (50 mL, 250 mL, 500 mL); 25% (20 mL, 50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flexbumin: 5% (250 mL); 25% (50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Human Albumin Grifols: 25% (50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kedbumin: 25% (50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plasbumin-5: 5% (50 mL, 250 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plasbumin-25: 25% (20 mL, 50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5% (100 mL, 250 mL, 500 mL); 25% (50 mL, 100 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130876\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050833\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: IV: Too rapid infusion may result in vascular overload. Rate of infusion dependent upon use. In emergencies, may administer as rapidly as necessary to improve clinical condition. After initial volume replacement: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">5%: Do not exceed 2 to 4 mL/minute in patients with normal plasma volume; 5 to 10 mL/minute in patients with hypoproteinemia </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">25%: Do not exceed 1 mL/minute in patients with normal plasma volume; 2 to 3 mL/minute in patients with hypoproteinemia  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Product-specific details:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Albuminar: May administer via the administration set provided (in-line 60 micron filter) or via any administration set; use of filter is optional; size of filter may vary according to institutional policy. Method of filter sterilization used by manufacturer includes 0.2 micron filter; however, aggregates may form under storage, shipping, and handling. Administration via very small filter will not damage product, but will slow flow rate. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Albutein: May administer via the administration set provided (in-line 50 micron filter) or via any administration set; use of filter is optional; size of filter may vary according to institutional policy. Method of production includes passage through 0.22 micron filter. May administer via filter as small as 0.22 microns. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Buminate: Administer via the administration set provided (in-line 15 micron filter) or via any filtered administration set; use &ge;5 micron filter to ensure adequate flow rate </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Plasbumin: May administer with or without an IV filter; filter as small as 0.22 microns may be used </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130899\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at &le;30&deg;C (86&deg;F); do not freeze. Do not use solution if it is turbid or contains a deposit; use within 4 hours after opening vial; discard unused portion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050832\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of hemolytic anemia of the newborn (FDA approved in neonates); treatment of hypovolemia (FDA approved in pediatric patients [age not specified] and adults); plasma volume expansion and maintenance of cardiac output in the treatment of certain types of shock or impending shock (FDA approved in pediatric patients [age not specified] and adults); may be useful to treat hypoalbuminemia in burn patients, ARDS, severe nephrosis, and cardiopulmonary bypass; unless the condition responsible for hypoproteinemia can be corrected, albumin can provide only symptomatic relief or supportive treatment; has also been used for large volume paracentesis, nephrotic syndrome, neonatal hypotension, and ascites. <b>Note:</b> Safety and efficacy in pediatric patients based on previously demonstrated clinical experience with albumin; product specific data may not be available.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130929\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Albuminar-25 (albumin) may be confused with Privigen (immune globulin) due to similar packaging</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Albutein may be confused with albuterol </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Buminate may be confused with bumetanide</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130926\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac failure (precipitation), edema, hypertension, hypotension, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypervolemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, pulmonary edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130894\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to albumin or any component of the formulation; severe anemia, heart failure; patients at risk of volume overload (eg, patients with renal insufficiency, severe anemia, stabilized chronic anemia, or heart failure); dilution with sterile water for injection (may cause hemolysis or acute renal failure)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130880\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Severe allergic or anaphylactic reaction may occur. Discontinue immediately and manage appropriately if allergic or anaphylactic reactions are suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Coagulation abnormality: Large replacement volumes may result in coagulation abnormality. Monitor and replete with blood constituents if indicated. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte imbalance: Large replacement volumes may result in electrolyte imbalance. Monitor electrolytes and replace or maintain as indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemodynamic effects: Cardiac or respiratory failure, renal failure, or increasing intracranial pressure can occur; closely monitor hemodynamic parameters in all patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypervolemia/hemodilution: Use with caution in conditions where hypervolemia and its consequences or hemodilution may increase the risk of adverse effects (eg, heart failure, pulmonary edema, hypertension, hemorrhagic diathesis, esophageal varices). Adjust rate of administration per hemodynamic status and solution concentration; monitor closely with rapid infusions. Avoid rapid infusions in patients with a history of cardiovascular disease (may cause circulatory overload and pulmonary edema). Discontinue at the first signs of cardiovascular overload (eg, headache, dyspnea, jugular venous distention, rales, abnormal elevations in systemic or central venous blood pressure). All patients should be observed for signs of hypervolemia, such as pulmonary edema. Monitor blood pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Critical illness: In patients with increased microvascular permeability (eg, sepsis,  trauma, burn), the translocation of fluid from the interstitial compartment to the intravascular compartment may decrease due to increased albumin in the interstitial space. Furthermore, in extreme microvascular permeability states, administration of albumin (or other colloids) may increase the net flux of fluid into the interstitial space reducing intravascular volume and precipitating edematous states (eg, pulmonary edema) (Roberts, 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; protein load may exacerbate or precipitate encephalopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; protein load may precipitate azotemia. Patients with chronic renal insufficiency receiving albumin solution may be at risk for accumulation of aluminum and potential toxicities (eg, hypercalcemia, vitamin D refractory osteodystrophy, anemia, severe progressive encephalopathy).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sodium restricted patients: Use with caution in those patients for whom sodium restriction is necessary. Albumin 5% and 25% solutions contain 130 to 160 mEq/L sodium and are considered isotonic with plasma.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aluminum: The parenteral product may contain aluminum (Kelly, 1989); toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dilution: Do not dilute 5% albumin with sterile water for injection (may result in hemolysis and/or renal failure).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Latex: Packaging may contain natural latex rubber.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819725\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In neonates, use the 25% concentration with extreme caution due to risk of intraventricular hemorrhage (from rapid expansion of the intravascular volume); infuse slowly. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Due to the occasional shortage of 5% human albumin, 5% solutions may at times be prepared by diluting 25% human albumin with NS or with D<sub>5</sub>W (if sodium load is a concern); however, do not use sterile water to dilute albumin solutions, as this may result in hypotonic-associated hemolysis which can be fatal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298693\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130884\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13277&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130886\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13334387\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Available data is insufficient to recommend use of albumin to reduce the risk of ovarian hyperstimulation syndrome (ASRM 2016). Use for other indications may be considered in pregnant women when contraindications to nonprotein colloids exist (Liumbruno 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050829\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Observe for signs of hypervolemia, pulmonary edema, cardiac failure, vital signs, fluid status, Hgb, Hct, urine specific gravity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130879\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Provides increase in intravascular oncotic pressure and causes mobilization of fluids from interstitial into intravascular space</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45653130\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;\">Half-life: 15 to 20 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050838\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">In certain conditions (eg, hypoproteinemia with generalized edema, nephrotic syndrome), doses of albumin may be followed with IV furosemide: 0.5 to 1 mg/kg/dose. </p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">Both albumin 5% and 25% contain 130 to 160 mEq/L of sodium; albumin 5% is osmotically equivalent to an equal volume of plasma; albumin 25% is osmotically equivalent to 5 times its volume of plasma.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322967\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Albuked 25 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25% (50 mL): $60.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Albuked 5 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (250 mL): $57.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Albumin Human Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (250 mL): $83.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25% (50 mL): $68.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Albuminar-25 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25% (50 mL): $112.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Albuminar-5 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (250 mL): $112.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Albutein Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (250 mL): $62.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25% (50 mL): $59.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Buminate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (250 mL): $131.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25% (20 mL): $131.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Flexbumin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (250 mL): $69.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25% (50 mL): $69.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Human Albumin Grifols Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25% (50 mL): $108.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Plasbumin-25 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25% (50 mL): $59.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Plasbumin-5 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (50 mL): $39.12</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130897\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acebumin (PE);</li>\n      <li>Alba (IN);</li>\n      <li>Albapure (ID, TW);</li>\n      <li>Albiomin (TH);</li>\n      <li>Albotein (IT);</li>\n      <li>Albuman (IS, MT);</li>\n      <li>Albumar (MX);</li>\n      <li>Albumax (PH);</li>\n      <li>Albumer (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Albumex (AU, NZ);</li>\n      <li>Albumex 20 (HK);</li>\n      <li>Albumin 5% (CH);</li>\n      <li>Albumin 5% Human (DE);</li>\n      <li>Albumin Human Salzarm 25% (DE);</li>\n      <li>Albumina Humana (BR, CU);</li>\n      <li>Albuminar (BR, ID, IL, PH, VN);</li>\n      <li>Albuminar 25 (TH);</li>\n      <li>Albuminativ (AT, SE);</li>\n      <li>Albuminative (QA, SA);</li>\n      <li>Albunate (MX);</li>\n      <li>Albunorm (BG, HR, HU, IE, LU, LV, NO, PH, RO, SI, UA);</li>\n      <li>Alburel (PH);</li>\n      <li>Alburex (CO, CY);</li>\n      <li>Alburx (CN);</li>\n      <li>Albusol (ZA);</li>\n      <li>Albutein (AE, BH, HR, LB, LK, PH, SA, VN);</li>\n      <li>Albutein 25% (BR, CN, HK);</li>\n      <li>Biseko (PL);</li>\n      <li>Buminate (SA);</li>\n      <li>Buminate 25% (HK, PH);</li>\n      <li>Cealb (AE);</li>\n      <li>Flexbumin (CZ, IE, LV, SK, VN);</li>\n      <li>Human Albumin 25% (DE);</li>\n      <li>Human Albumin 5% (DE);</li>\n      <li>Kedrialb (PH);</li>\n      <li>Octalbin (DK, ES, FI, ID, MX);</li>\n      <li>Plasbumin (AE, ID, LB, SG);</li>\n      <li>Seralbumin (CR, DO, GT, HN, PA, PY, SV);</li>\n      <li>Seroalbumin (PH);</li>\n      <li>SRK (CH);</li>\n      <li>Vialebex (FR);</li>\n      <li>Volumin (IN);</li>\n      <li>Zenalb (GR, ID, MT, SG, TH, VN);</li>\n      <li>Zenalb 20 (CO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Albuminar-20 (albumin) [prescribing information]. Kankakee, IL: CSL Behring LLC; August 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Albuminar-25 (albumin) [prescribing information]. Kankakee, IL: CSL Behring LLC; August 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Albutein (albumin) [prescribing information]. Los Angeles, CA: Grifols Biologicals Inc; July 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Society for Reproductive Medicine (ASRM) Practice Committee, &quot;Ovarian Hyperstimulation Syndrome,&quot; <i>Fertil Steril</i>, 2008, 90(5 Suppl):188-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-pediatric-drug-information/abstract-text/19007627/pubmed\" target=\"_blank\" id=\"19007627\">19007627</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buminate 5% (albumin) [prescribing information]. Westlake Village, CA: Baxter Healthcare Corporation; August 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buminate 25% (albumin) [prescribing information]. Westlake Village, CA: Baxter Healthcare Corporation; August 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cloherty JP, Eichenwald EC, Stark AR, eds. <i>Manual of Neonatal Care</i>. 7th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. <i>Crit Care Med</i>. 2013;41(2):580-637.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-pediatric-drug-information/abstract-text/23353941 /pubmed\" target=\"_blank\" id=\"23353941 \">23353941 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Department Health and Human Services, Food Drug Administration, &quot;Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition,&quot; <i>Federal Register</i>, 2000, 65(17):4103-11.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flexbumin 5% (albumin) [prescribing information]. Westlake Village, CA: Baxter Healthcare Corporation; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giefer MJ, Murray KF, Colletti RB. Pathophysiology, diagnosis, and management of pediatric ascites. <i>J Pediatr Gastroenterol Nutr</i>. 2011;52(5):503-513.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-pediatric-drug-information/abstract-text/21464748 /pubmed\" target=\"_blank\" id=\"21464748 \">21464748 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gipson DS, Massengill SF, Yao L, et al. Management of childhood onset nephrotic syndrome. <i>Pediatrics</i>. 2009;124(2):747-757.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-pediatric-drug-information/abstract-text/19651590 /pubmed\" target=\"_blank\" id=\"19651590 \">19651590 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Hemolysis Associated With 25% Human Albumin Diluted With Sterile Water - United States, 1994-1998,&rdquo; <i>MMWR Morb Mortal Wkly Rep</i>, 1999, 48(8):157-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-pediatric-drug-information/abstract-text/10079061/pubmed\" target=\"_blank\" id=\"10079061\">10079061</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kattwinkel J, Perlman JM, Aziz K,et al. Part 15: neonatal resuscitation: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2010;122(18 Suppl 3):S909-919.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-pediatric-drug-information/abstract-text/20956231/pubmed\" target=\"_blank\" id=\"20956231\">20956231</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kedbumin (albumin) [prescribing information]. Fort Lee, NJ: Kedrion Biopharma, Inc; June 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly AT, Short BL, Rains TC, May JC, Progar JJ. Aluminum toxicity and albumin. <i>ASAIO Trans</i>. 1989;35(3):674-676.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-pediatric-drug-information/abstract-text/2597561 /pubmed\" target=\"_blank\" id=\"2597561 \">2597561 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2010;122(18 Suppl 3):S876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-pediatric-drug-information/abstract-text/20956230 /pubmed\" target=\"_blank\" id=\"20956230 \">20956230 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kramer RE, Sokol RJ, Yerushalmi B, et al. Large-volume paracentesis in the management of ascites in children.<i> J Pediatr Gastroenterol Nutr</i>. 2001;33(3):245-249.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-pediatric-drug-information/abstract-text/11593116 /pubmed\" target=\"_blank\" id=\"11593116 \">11593116 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liumbruno GM, Bennardello F, Lattanzio A, et al, &quot;Recommendations for the Use of Albumin and Immunoglobulins,&quot; <i>Blood Transfus</i>, 2009, 7(3):216-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-pediatric-drug-information/abstract-text/19657486/pubmed\" target=\"_blank\" id=\"19657486\">19657486</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lynch SK, Mullett MD, Graeber JE, et al, &quot;A Comparison of Albumin-Bolus Therapy Versus Normal Saline-Bolus Therapy for Hypotension in Neonates,&quot; <i>J Perinatol</i>, 2008, 28(1):29-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-pediatric-drug-information/abstract-text/17989698/pubmed\" target=\"_blank\" id=\"17989698\">17989698</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oca MJ, Nelson M, Donn SM. Randomized trial of normal saline versus 5% albumin for the treatment of neonatal hypotension. <i>J Perinatol</i>. 2003;23(6):473-476.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-pediatric-drug-information/abstract-text/13679934 /pubmed\" target=\"_blank\" id=\"13679934 \">13679934 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plasbumin (albumin) [prescribing information]. Research Triangle Park, NC: Talecris Biotherapeutics, Inc; April 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roberts JS and Bratton SL, Colloid volume expanders. Problems, pitfalls, and possibilities. Drugs, 1998, 55(5):621-630.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-pediatric-drug-information/abstract-text/9585860/pubmed\" target=\"_blank\" id=\"9585860\">9585860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson RF, Nahata MC, Mahan JD, Batisky DL. Management of nephrotic syndrome in children. <i>Pharmacotherapy</i>. 2003;23(8):1021-1036.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-pediatric-drug-information/abstract-text/12921248 /pubmed\" target=\"_blank\" id=\"12921248 \">12921248 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sabri M, Saps M, Peters JM. Pathophysiology and management of pediatric ascites.<i> Curr Gastroenterol Rep</i>. 2003;5(3):240-246.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-pediatric-drug-information/abstract-text/12734047 /pubmed\" target=\"_blank\" id=\"12734047 \">12734047 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wyckoff MH, Aziz K, Escobedo MB, et al. Part 13: neonatal resuscitation: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2015;132(18 Suppl 2):S543-560.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13277 Version 117.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F130903\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F130904\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1050830\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11431407\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1050824\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F130890\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F130876\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1050833\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F130899\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1050832\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F130929\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F130926\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F130894\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F130880\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819725\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298693\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F130884\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F130886\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13334387\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1050829\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F130879\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F45653130\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1050838\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322967\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F130897\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13277|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=albumin-solution-drug-information\" class=\"drug drug_general\">Albumin solution: Drug information</a></li><li><a href=\"topic.htm?path=albumin-solution-patient-drug-information\" class=\"drug drug_patient\">Albumin solution: Patient drug information</a></li></ul></div></div>","javascript":null}